Table 6. Outcomes after repeat CRS/HIPEC for mesothelioma.
| Author (citation) | Study type | Year | N | PCI | Median overall survival (months) | Median disease free survival (months) | Median follow-up (months) | Morbidity (grade 3 and 4) | Mortality | CC 0-1 |
|---|---|---|---|---|---|---|---|---|---|---|
| Magge et al. (75) | P | 2014 | 65 | 12 (median) | 46.2 | 13.9 | 37.0 | 35.0% | 6.0% | 100.0% |
| Chua et al. (80) | R | 2011 | 26 | 14 (median) | NA (12 patients have survived more than 5 years) | NA | 54.0 | 23.1% | 0.0% | 92.3% |
| Brigand et al. (86) | P | 2006 | 15 | NA | 35.6 | NA | 46.7 | 40.0% | 0.0% | 73.3% |
| Feldman et al. (87) | R | 2003 | 49 | NA | 92.0 | 17.0 | 28.3 | 25.0% | NA | 46.9% |
| Deraco et al. (88) | R | 2006 | 49 | NA | 5-year 57% | 39.7 | 20.3 (mean) | 12.0% | 0.0% | NA |
| Wong et al. (95) | R | 2014 | 29 | 16 (median) | 41.2 | NA | 12.2 | 65.0% | 4.0% | 78.0% |
| Ihemelandu et al. (96) | R | 2015 | 44 | 18 (mean) | 54.0 | NA | 28.0 | 2.3% | 0.0% | 46.6% |
CRS, cytoreductive surgery; HIPEC, hyperthermic intraperitoneal chemotherapy; P, prospective; R, retrospective; N, number of patients; PCI, peritoneal cancer index; CC, completeness of cytoreduction; NA, not available.